SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001785530-21-000009
Filing Date
2021-05-28
Accepted
2021-05-28 08:02:26
Documents
12
Period of Report
2021-05-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K howl-20210527.htm   iXBRL 8-K 35827
  Complete submission text file 0001785530-21-000009.txt   182326

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20210527.xsd EX-101.SCH 1946
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20210527_lab.xml EX-101.LAB 25848
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20210527_pre.xml EX-101.PRE 13621
5 EXTRACTED XBRL INSTANCE DOCUMENT howl-20210527_htm.xml XML 12247
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

IRS No.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 21976164
SIC: 2834 Pharmaceutical Preparations